Markers of Iron Deficiency in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy

This exploratory analysis, the first to evaluate iron status in a prospective study of patients with polycythemia vera, investigated ruxolitinib effects on 7 serum iron markers and iron deficiency-related patient-reported outcomes.

 Leuk Res

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.